Anti-Human MUSK Antibody (SAA1506)

Catalog No.

RHA43101

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

MuSK, MUSK, Muscle-specific kinase receptor, Muscle, skeletal receptor tyrosine-protein kinase, Muscle-specific tyrosine-protein kinase receptor

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O15146

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1506

MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis., PMID:40504622

MGBase: A Global, Observational Registry for Collaborative Research in Myasthenia Gravis., PMID:40468746

Myasthenia Gravis Presenting With Vocal Cord Paralysis As the Initial Symptom Occurring One Week Following Herpes Zoster Vaccination: A Case Report and Review of the Literature., PMID:40462824

The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis., PMID:40422242

The Fusion Protein MuSK-Fc Functions as a Decoy to Block the Binding of Anti-MuSK Antibodies to MuSK., PMID:40411208

Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review., PMID:40356916

Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects., PMID:40277145

[Treatment and clinical course of autoimmune myasthenia in Burkina Faso]., PMID:40248578

Long-Term Swallowing Rehabilitation for Muscle-Specific Tyrosine Kinase Antibody-Positive Myasthenia Gravis: A Case Report., PMID:40225522

Pyridostigmine-induced complete atrioventricular block in a patient with Musk antibody-negative myasthenia gravis a case report : Pyridostigmine-ind advanced AV block in MG patient with MuSK-neg., PMID:40148780

Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis., PMID:40144041

Testing for Acetylcholine Receptor and Muscle-Specific Tyrosine Kinase Antibodies by Fixed Cell-Based Assay in Clinical Practice: Positive Predictive Value for Myasthenia Gravis., PMID:40130472

Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experience., PMID:40128464

Clinical Spectrum and Therapeutic Outcome of Myasthenia Gravis in a Tertiary Care Hospital: A Retrospective Study., PMID:40087931

Prevalence and course of muscle-specific receptor tyrosine kinase (MuSK) antibodies in myasthenia gravis - A retrospective study., PMID:40086234

Efficacy and safety of different dosages of rituximab for myasthenia gravis: a single-arm meta-analysis., PMID:40085401

Successful treatment with refractory myasthenia gravis that developed after allogeneic hematopoietic stem cell transplantation: two case reports., PMID:40083543

Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data., PMID:40069719

Development and Application of a Cell-Based Assay for Detecting Anti-Agrin Antibodies Associated With Myasthenia Gravis., PMID:40065451

A Case of Myasthenia Gravis: A Paraneoplastic Syndrome or an Immune-Related Disorder?, PMID:40062097

Double-seropositive Myasthenia Gravis Following COVID-19., PMID:40058857

Prevalence and incidence rates of 17 neuromuscular disorders: An updated review of the literature., PMID:40034005

Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension., PMID:40034001

Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions., PMID:40033991

Unusual presentations of myasthenia gravis and misdiagnosis., PMID:40032968

Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis., PMID:40021769

Young child with MuSK myasthenia gravis: treatment and remission with rituximab., PMID:40000033

Clinical Outcomes of Rituximab Infusion Among Refractory Myasthenia Gravis Patients in the Philippines: A 10-Year Retrospective Study., PMID:39991399

Autoantibodies in myasthenia gravis: cluster analysis and clinical correlations., PMID:39968461

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models., PMID:39898046

Orbicularis Oculi Stimulated Jitter Analysis in Children With Autoimmune Myasthenia Gravis., PMID:39887421

Concomitant Exacerbation of Graves Orbitopathy and Double-Seronegative Myasthenia Gravis after SARS-CoV-2 Infection., PMID:39882352

Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial., PMID:39862880

Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study., PMID:39862879

Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study., PMID:39839222

Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders., PMID:39708835

A clinical perspective on muscle specific kinase antibody positive myasthenia gravis., PMID:39703505

Advances in B Cell Targeting for Treating Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis., PMID:39678139

Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation., PMID:39628891

Surgical treatment of thymic epithelial tumor and myasthenia gravis., PMID:39624461

Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review., PMID:39624088

McHDV VP60 Virus-like Particles Elicit Protective Immunity Against Moschus chrysogaster Hemorrhagic Disease in Rabbits., PMID:39599478

Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study., PMID:39503950

Complications of Long COVID: Unraveling a Case of Very-Late-Onset Myasthenia Gravis., PMID:39479090

Isolated Respiratory Failure as the Presenting Symptom of Muscle-Specific Kinase Myasthenia Gravis: A Case Report and Literature Review., PMID:39474296

[Efficacy and safety of rituximab in the treatment of pediatric myasthenia gravis]., PMID:39429076

Clinical Characteristics of Double Seropositive Myasthenia Gravis., PMID:39428782

275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9-11 February 2024, Hoofddorp, the Netherlands., PMID:39427494

Laryngeal Myasthenia Gravis in Voice Patients: Clinical, Serologic, and Neuromuscular Characterization of Seronegative Patients for Antibodies Against the Acetylcholine Receptor and Muscle-Specific Kinase., PMID:39419706

Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis., PMID:39385818

Document Download

Anti-Human MUSK Antibody (SAA1506).pdf